Who is sponsoring NCT01799057?

NCT01799057 is sponsored by Baker Heart and Diabetes Institute.

What condition does NCT01799057 study?

NCT01799057 studies Peripheral Arterial Disease, Intermittent Claudication.

What drugs are being tested in NCT01799057?

Interventions: Metformin, Placebo.

What is the status of NCT01799057?

NCT01799057 is currently TERMINATED.

Last reviewed 2016-02-07 · How we verify

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of Metformin for the Assessment of Changes in Functional Capacity, Endothelial Function, and Hemodynamics in Individuals With Peripheral Artery Disease-Related Intermittent Claudication

NCT01799057 Phase 4 TERMINATED

The purpose of this study is to determine the effects of metformin on functional capacity (pain-free and maximum walking times) in individuals with peripheral artery disease (PAD)-related intermittent claudication.

Details

Lead sponsor	Baker Heart and Diabetes Institute
Phase	Phase 4
Status	TERMINATED
Enrolment	2
Start date	2013-07
Completion	2014-12

Conditions

Peripheral Arterial Disease
Intermittent Claudication

Interventions

Metformin
Placebo

Primary outcomes

Change in pain-free walking time — Measured at baseline and following 16-18 weeks treatment
Pain-free walking time (time to onset of claudication) will be measured during a graded treadmill exercise test.
Change in maximum walking time — Measured at baseline and following 16-18 weeks treatment
Maximum walking time will be measured during a graded treadmill exercise test.

Countries

Australia